Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00124566 · ClinicalTrials.gov registry record · Phase 2
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
NCT00124566 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 135 participants.
The verdict
NCT00124566, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of irofulven-based regimens compared to mitoxantrone plus prednisone in patients with hormone-refractory prostate cancer (HRPC) whose disease has progressed following Taxotere based regimens.
Interventions
- DRUG Capecitabine
- DRUG Prednisone
- DRUG Mitoxantrone
- DRUG Irofulven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2004-06 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00124566
The ClinicalTrials.gov registry entry for NCT00124566 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Capecitabine is the first listed.
NCT00124566 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00124566 about?
NCT00124566 is a clinical study titled "Study of Irofulven in Patients With Hormone-refractory Prostate Cancer". The purpose of this study is to assess the efficacy and safety of irofulven-based regimens compared to mitoxantrone plus prednisone in patients with hormone-refractory prostate cancer (HRPC) whose disease has progressed following Taxotere based regimens.
What is the current status of trial NCT00124566?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2004-06. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00124566?
The interventions under investigation include: Capecitabine (DRUG), Prednisone (DRUG), Mitoxantrone (DRUG), Irofulven (DRUG).
Who is sponsoring clinical trial NCT00124566?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.